BIOMERICA INC
BMRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BMRA
Biomerica Inc (BMRA) is a diagnostics and medical device company focused on developing products for gastrointestinal and inflammatory diseases, currently facing significant liquidity challenges and a going concern risk.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Feb 28, 2026.
Tracking 7 clinical trials for BIOMERICA INC.
Biomerica Inc (BMRA) is a diagnostics and medical device company focused on developing products for gastrointestinal and inflammatory diseases, currently facing significant liquidity challenges and a going concern risk.
- Cash and cash equivalents were $1.3M as of February 28, 2026 [sec_mda · as of 2026-04-13].
- Total revenue was $1.0M and net income was -$1.3M for the three months ended February 28, 2026 [latest reported financials].
- The company has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-04-13].
- Management is pursuing strategies including cost reductions, asset sales, and additional financing to address capital needs [sec_mda · as of 2026-04-13].
What works
- The company has a shelf registration statement effective through September 2026, allowing issuance of up to $20M in common stock to raise capital [sec_mda · as of 2025-08-29].
- Net proceeds of approximately $1.455M were raised from an ATM offering in early 2026, strengthening liquidity [sec_mda · as of 2026-04-13].
- Cost-cutting measures, including a workforce reduction of nearly 16%, have been implemented to extend cash runway [sec_mda · as of 2025-08-29].
What to weigh
- Cash and cash equivalents declined from $2.399M (May 31, 2025) to $1.336M (February 28, 2026) [sec_mda · as of 2026-04-13].
- The company has a going concern risk, with management stating current cash is insufficient for the next twelve months [sec_mda · as of 2026-04-13].
- Revenue from clinical lab sales decreased by 1% year-over-year for the three months ended February 28, 2026 [sec_mda · as of 2026-04-13].
- The company has an accumulated deficit and relies on external financing to sustain operations [sec_mda · as of 2026-04-13].
From the filings
Quoted directly from source documents.
Going concern risk
“These factors raise substantial doubt about our ability to continue as a going concern.”
SEC MD&A · April 13, 2026
Cost-cutting measures including workforce reduction
“we have initiated significant cost-cutting measures to extend our cash runway and work towards increasing revenues to cover overhead costs. These measures include a workforce reduction of nearly 16%”
SEC MD&A · August 29, 2025
ATM offering proceeds
“the Company strengthened its liquidity position through a combination of operating cost controls, and net proceeds of approximately $1,455,000 from the ATM offering.”
SEC MD&A · April 13, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-04-13].
- Insufficient liquidity — Cash and equivalents of $1.3M as of February 28, 2026 are deemed insufficient for the next twelve months [sec_mda · as of 2026-04-13].
- Dependence on external financing — The company relies on debt or equity financing to sustain operations, with no guarantee of availability [sec_mda · as of 2026-04-13].
- Revenue decline in core segment — Clinical lab revenue decreased by 1% year-over-year for the three months ended February 28, 2026 [sec_mda · as of 2026-04-13].
What to watch
- Ability to secure additional financing through the shelf registration or other means [sec_mda · as of 2026-04-13].
- Progress on cost-cutting measures and their impact on cash runway [sec_mda · as of 2025-08-29].
- Revenue trends from clinical lab and new product launches [sec_mda · as of 2026-04-13].
- Any strategic alternatives or asset sales that may be pursued [sec_mda · as of 2026-04-13].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run BIOMERICA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOMERICA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
5.2 months
D/E 0.47 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$235K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 56,042 | $118K |
| vanguard capital management llc | 29,028 | $61K |
| blackrock, inc. | 18,636 | $40K |
| vanguard fiduciary trust co | 6,613 | $14K |
| hollencrest capital management | 825 | $2K |
| harbour investments, inc. | 125 | $265 |
| danske bank a/s | 1 | $2 |
Short Interest
as of May 20, 2026- % of float
- 2.3%
- Days to cover
- 4.2
- Shares short
- 63,380
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BMRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIOMERICA INC?
Biomerica Inc (BMRA) is a diagnostics and medical device company focused on developing products for gastrointestinal and inflammatory diseases, currently facing significant liquidity challenges and a going concern risk.
Who is the CEO of BIOMERICA INC?
Mr. Zackary S. Irani is the chief executive officer of BIOMERICA INC (BMRA).
Where is BIOMERICA INC headquartered?
BIOMERICA INC (BMRA) is headquartered in Irvine, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.